Ticker

No recent analyst price targets found for BNXTF.

Latest News for BNXTF

BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for…

Accesswire • Aug 26, 2026
BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants

VANCOUVER, BC / ACCESS Newswire / August 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that it has closed its previously announced extension of unsecured convertible debentures (the "Debentures"), as initially disclosed in its news releases dated June 10 and 23, 2026. The Company amended the terms of the Debentures in the principal amounts of…

Accesswire • Aug 21, 2026
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies

VANCOUVER, BC / ACCESS Newswire / August 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for…

Accesswire • Aug 19, 2026
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

VANCOUVER, BC / ACCESS Newswire / August 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs,…

Accesswire • Aug 17, 2026
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

VANCOUVER, BC / ACCESS Newswire / August 4, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including…

Accesswire • Aug 4, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for BNXTF.

No Senate trades found for BNXTF.

No House trades found for BNXTF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top